November 25, 2025

111. Pulm PEEPs Pearls: Methylene Blue

7 minutes

Furf and Monty are back today with another Pulm PEEPs Pearls episode, and discussing the use of methylene blue for patients with septic shock. They review the clinical scenarios when this comes up, the mechanism, some key data, and some take aways, all in 15 minutes! Let us know any other topics you’d like covered on the show and make sure to like, give us 5 stars, and subscribe wherever you’re listening to this podcast.

This episode was prepared in conjunction with George Doumat MD. Goerge is an internal medicine resident at UT Southwestern and joined us for a Pulm PEEPs – BMJ Thorax journal club episode. He is now acting as a Pulm PEEPs Associate Editor for the Pulm PEEPs Pearls series.

Key Learning Points

Clinical context: when does methylene blue even come up?

This is not a first-line sepsis drug.

It’s considered in catecholamine-refractory vasoplegic septic shock, typically when:

Norepinephrine is at high dose

Vasopressin is on board

Often a 3rd or 4th vasopressor is being used (e.g., phenylephrine, angiotensin II)

The phenotype is strongly vasodilatory/vasoplegic (warm, distributive shock) rather than primarily cardiogenic.

Mechanism of action (why it might help)

Methylene blue:

Inhibits inducible nitric oxide synthase and guanylate cyclase.

Blunts excess nitric oxide and cyclic GMP–mediated vasodilation, which are key in vasoplegic sepsis.

Practical translation:

It restores vascular tone and can make the vasculature more responsive to catecholamines.

It’s also used in post-CPB vasoplegia (e.g., after cardiac surgery, especially in patients on ACE inhibitors) and has migrated from that world into ICU sepsis practice.

Typical dosing strategy (as described in the episode)

Common approach:

1–3 mg/kg IV bolus, then

Reassess hemodynamics (MAP, dynamic perfusion markers).

If there’s a response, consider a continuous infusion or repeat bolus.

Key nuance: unlike other pressors that start as drips, methylene blue is often trialed as a bolus first to see if it’s doing anything.

What does the evidence suggest?

Most data are from small, single-center, heterogeneous studies, so evidence quality is low. Meta-analyses and systematic reviews (through ~2024–25) suggest:

Hemodynamics

Can increase MAP (roughly 1–10 mmHg across studies).

May shorten total vasopressor duration (one meta-analysis ~30 hours less, though this is not definitive).

Secondary physiologic effects

Some small improvements in PaO₂/FiO₂ (P/F) ratio in certain studies.

Clinical outcomes

Possible reduction in hospital length of stay (≈ up to 2 days in some pooled analyses).

Some signal toward lower short-term mortality, but:

Studies are small

Heterogeneous

Evidence is very low certainty

Bottom line:

There’s a repeatable signal that methylene blue:

Raises MAP

Helps reduce catecholamine requirements

But hard clinical outcomes (mortality, LOS, ventilator days) remain uncertain.

Safety profile & important adverse effects

Things to watch for:

Methemoglobinemia

Serotonin syndrome

Especially in patients on SSRIs, though in life-threatening refractory shock the hosts still lean toward using it with caution.

Pulse oximeter artifact

Can distort SpO₂ readings.

Urine discoloration

Blue/green urine—benign but striking.

Notably:

Methylene blue is both a treatment for and a potential cause of methemoglobinemia, depending on context and dosing.

Guidelines & where it fits in practice

Surviving Sepsis Campaign 2021:

Does not recommend methylene blue for routine use in septic shock.

No major critical care society includes it in standard septic shock bundles or protocols.

The hosts frame methylene blue as:

A rescue therapy, not guideline therapy.

Something to consider only in refractory vasoplegic shock, ideally with:

Multidisciplinary discussion (intensivist, pharmacist, etc.).

Clear documentation that this is off-guideline, salvage use.

Practical bedside framing (“2 a.m. in the ICU”)

They emphasize three pillars of practice:

Physiology – mechanism makes sense (NO / cGMP / vasodilation).

Empiric evidence – small studies and meta-analyses show a signal but low-quality data.

Bedside reality – at 2 a.m., with a patient in multi-pressor, refractory vasoplegic shock, you sometimes reach for imperfect tools.

So, the practical take:

You should NOT:

Use methylene blue early.

Treat it as part of standard sepsis care.

You may consider it when:

Shock is clearly vasoplegic and refractory.

Norepi + vasopressin + at least one more vasopressor are maxed.

Team agrees this is salvage therapy and understands the limited evidence and side effects.

...more

View all episodes

By PulmPEEPs

4.9

5555 ratings

November 25, 2025

111. Pulm PEEPs Pearls: Methylene Blue

7 minutes

Key Learning Points

Clinical context: when does methylene blue even come up?

This is not a first-line sepsis drug.

It’s considered in catecholamine-refractory vasoplegic septic shock, typically when:

Norepinephrine is at high dose

Vasopressin is on board

Often a 3rd or 4th vasopressor is being used (e.g., phenylephrine, angiotensin II)

The phenotype is strongly vasodilatory/vasoplegic (warm, distributive shock) rather than primarily cardiogenic.

Mechanism of action (why it might help)

Methylene blue:

Inhibits inducible nitric oxide synthase and guanylate cyclase.

Blunts excess nitric oxide and cyclic GMP–mediated vasodilation, which are key in vasoplegic sepsis.

Practical translation:

It restores vascular tone and can make the vasculature more responsive to catecholamines.

It’s also used in post-CPB vasoplegia (e.g., after cardiac surgery, especially in patients on ACE inhibitors) and has migrated from that world into ICU sepsis practice.

Typical dosing strategy (as described in the episode)

Common approach:

1–3 mg/kg IV bolus, then

Reassess hemodynamics (MAP, dynamic perfusion markers).

If there’s a response, consider a continuous infusion or repeat bolus.

Key nuance: unlike other pressors that start as drips, methylene blue is often trialed as a bolus first to see if it’s doing anything.

What does the evidence suggest?

Most data are from small, single-center, heterogeneous studies, so evidence quality is low. Meta-analyses and systematic reviews (through ~2024–25) suggest:

Hemodynamics

Can increase MAP (roughly 1–10 mmHg across studies).

May shorten total vasopressor duration (one meta-analysis ~30 hours less, though this is not definitive).

Secondary physiologic effects

Some small improvements in PaO₂/FiO₂ (P/F) ratio in certain studies.

Clinical outcomes

Possible reduction in hospital length of stay (≈ up to 2 days in some pooled analyses).

Some signal toward lower short-term mortality, but:

Studies are small

Heterogeneous

Evidence is very low certainty

Bottom line:

There’s a repeatable signal that methylene blue:

Raises MAP

Helps reduce catecholamine requirements

But hard clinical outcomes (mortality, LOS, ventilator days) remain uncertain.

Safety profile & important adverse effects

Things to watch for:

Methemoglobinemia

Serotonin syndrome

Especially in patients on SSRIs, though in life-threatening refractory shock the hosts still lean toward using it with caution.

Pulse oximeter artifact

Can distort SpO₂ readings.

Urine discoloration

Blue/green urine—benign but striking.

Notably:

Methylene blue is both a treatment for and a potential cause of methemoglobinemia, depending on context and dosing.

Guidelines & where it fits in practice

Surviving Sepsis Campaign 2021:

Does not recommend methylene blue for routine use in septic shock.

No major critical care society includes it in standard septic shock bundles or protocols.

The hosts frame methylene blue as:

A rescue therapy, not guideline therapy.

Something to consider only in refractory vasoplegic shock, ideally with:

Multidisciplinary discussion (intensivist, pharmacist, etc.).

Clear documentation that this is off-guideline, salvage use.

Practical bedside framing (“2 a.m. in the ICU”)

They emphasize three pillars of practice:

Physiology – mechanism makes sense (NO / cGMP / vasodilation).

Empiric evidence – small studies and meta-analyses show a signal but low-quality data.

Bedside reality – at 2 a.m., with a patient in multi-pressor, refractory vasoplegic shock, you sometimes reach for imperfect tools.

So, the practical take:

You should NOT:

Use methylene blue early.

Treat it as part of standard sepsis care.

You may consider it when:

Shock is clearly vasoplegic and refractory.

Norepi + vasopressin + at least one more vasopressor are maxed.

Team agrees this is salvage therapy and understands the limited evidence and side effects.

...more

More shows like PulmPEEPs

View all

EMCrit FOAM Feed

1,867 Listeners

NEJM This Week

325 Listeners

JAMA Clinical Reviews

498 Listeners

The Curbsiders Internal Medicine Podcast

3,360 Listeners

Emergency Medical Minute

260 Listeners

Core IM | Internal Medicine Podcast

1,143 Listeners

Annals On Call Podcast

191 Listeners

The Internet Book of Critical Care Podcast

698 Listeners

The Clinical Problem Solvers

515 Listeners

Harrison's PodClass: Internal Medicine Cases and Board Prep

369 Listeners

Run the List

248 Listeners

Critical Care Scenarios

249 Listeners

Cardionerds: A Cardiology Podcast

426 Listeners

The Curious Clinicians

374 Listeners

Critical Care Time

269 Listeners

Share 111. Pulm PEEPs Pearls: Methylene Blue

Sign up to save your podcasts

111. Pulm PEEPs Pearls: Methylene Blue

111. Pulm PEEPs Pearls: Methylene Blue

More shows like PulmPEEPs

EMCrit FOAM Feed

NEJM This Week

JAMA Clinical Reviews

The Curbsiders Internal Medicine Podcast

Emergency Medical Minute

Core IM | Internal Medicine Podcast

Annals On Call Podcast

The Internet Book of Critical Care Podcast

The Clinical Problem Solvers

Harrison's PodClass: Internal Medicine Cases and Board Prep

Run the List

Critical Care Scenarios

Cardionerds: A Cardiology Podcast

The Curious Clinicians

Critical Care Time